“☄베스트토토안전【평생베스트.com】베스트토토안전☄”的搜索结果，显示 121-130 项，共有 8440 项

1. 耳鼻喉科(ENT) /头颈外科- 临床试验- 妙佑医疗国际

   The purpose of this study is to identify a biomarker (or biomarkers) that is present when disease is present (i.e., at diagnosis or recurrence) and not ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

6. 耳鼻喉科(ENT) /头颈外科- 临床试验- 妙佑医疗国际

   The purpose of this study is to identify a biomarker (or biomarkers) that is present when disease is present (i.e., at diagnosis or recurrence) and not ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...

8. 外科 - 临床试验- 妙佑医疗国际

   The pupose of this study is to evaluate whether or not selumetinib works just as well as the standard treatment with carboplatine/vincristine (CV) for ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...